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Abstract
Background—Practical and objective instruments to assess pediatric Crohn’s disease (CD)
activity are required for observational research and quality improvement.
Objectives—1) To determine the feasibility of completing the Pediatric Crohn’s Disease
Activity Index (PCDAI) and the Abbreviated PCDAI (APCDAI), and 2) To create a short PCDAI
by retaining and re-weighting the most practical and informative components.
Methods—Physicians in the ImproveCareNow Collaborative for pediatric inflammatory bowel
disease (IBD) were asked to record components of the PCDAI and assign a Physician Global
Assessment (PGA) of disease severity at each patient encounter. We assessed the feasibility of the
PCDAI, the APCDAI, and the individual index components by determining the proportion of
visits in which data were recorded. We created a short index by retaining and reweighting
components of the PCDAI completed in ≥80% of visits. The feasibility of the short PCDAI and its
ability to discriminate between PGA categories were evaluated using descriptive statistics.
Results—This study population included 1355 subjects with CD (6373 visits). The PCDAI and
APCDAI were complete in 16.7% and 44.1% of visits respectively. A short PCDAI, including
general well-being, abdominal pain, stools, weight, abdominal exam, and extra-intestinal
manifestations could be completed in 66.5% of visits. The correlation between the Short PCDAI
and PGA was similar to that of the PCDAI (r= 0.60, p<0.001 vs 0.61, p<0.001).
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Conclusion—The Short PCDAI is a practical and valid tool to measure pediatric CD activity
disease activity. Its use should facilitate quality improvement and observational research.
Background
Crohn’s disease (CD) is a chronic, relapsing disorder of the gastrointestinal tract which
affects nearly 600,000 Americans[1], including 50,000 children [2]. Nearly 25% of patients
experience onset of their disease during the childhood or adolescent years. Because
childhood-onset disease is associated with a high degree of patient morbidity including
missed work [3] and school[4], decreased quality of life[5,6], and psychosocial
disturbance[7,8], both clinical research and quality improvement approaches are necessary
to improve outcomes for affected patients.
A significant impediment to research in pediatric Crohn’s disease has been the difficulty in
selecting an appropriate outcome measure [9,10]. Disease activity indices, such as the
Pediatric Crohn’s Disease Activity Index (PCDAI) have been developed and validated as
endpoints for clinical trials[11]. However, due to problems inherent in both the funding and
recruitment for clinical trials (i.e. interventional studies), much of the research in pediatric
Crohn’s disease has relied on observational study designs such as patient registries and
retrospective chart reviews. Because the PCDAI requires determination of height velocity,
analysis of laboratory tests, and components of the physical exam (perirectal examination)
that are not always completed during patient encounters, the feasibility of this index in
observational studies has been called into question[12]. Consequently, a disease activity
index that can be easily completed in the context of routine clinical care would greatly
facilitate clinical research in pediatric Crohn’s disease. In addition, a more practical index
would also be helpful in measuring outcomes for quality improvement purposes, in
establishing performance benchmarks, and in assisting individual clinicians at the point of
care in making decisions about whether or not to step-up or adjust medical therapy.
Shortened activity indices have been previously developed for adult Crohn’s disease[13] and
ulcerative colitis[14] assessments, with good feasibility and overall accuracy. Although an
abbreviated PCDAI (APCDAI) has been previously proposed[15] and tested in a single
center study[16], this instrument has not been evalulated in a large, multi-center setting.
Furthermore, use of the APCDAI in observational research may be limited by the
requirement of a perirectal examination which is not always performed during routine clinic
visits.
The aims of this study were 1) To determine the feasibility of completing the PCDAI,
APCDAI, and their individual components in the context of routine clinical care, and 2) To
create a Short PCDAI by retaining and re-weighting the most practical and informative
components. To accomplish this, we performed an analysis of clinical and laboratory data
prospectively collected by centers participating in the ImproveCareNow Collaborative, a
quality improvement project for Crohn’s disease and ulcerative colitis (formerly known as
the PIBDNet Trailblazer Improvement Collaborative).
Methods
Study population
The ImproveCareNow Collaborative for pediatric inflammatory bowel disease (IBD) was
formed in April 2007 by 9 participating pediatric gastroenterology programs. Subsequently,
an additional 6 centers joined the network. In this quality improvement program, children
with previously and newly diagnosed IBD were enrolled during clinic visits, and followed
prospectively at each encounter. At the onset of the collaborative, a case report form was
designed to capture clinical and demographic information about each patient, including all
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of the components of the PCDAI as well as a Physician Global Assessment (PGA) of
disease severity. Physicians at participating sites were asked to complete each of these items
at each clinic visit.
Determination of PCDAI scores
For each patient visit, we scored each component of the PCDAI if sufficient data were
available. If the required data were not available, we considered the component as
incomplete and a score was not assigned. PCDAI component scores were assigned using the
methods described in the published user’s guide[10]. We calculated height velocity Z scores
based on Centers for Disease Control (CDC) height velocity growth charts, only if a prior
height and date were previously recorded 6–12 months prior to that visit. We based all Z
scores on chronological age, as bone age and Tanner staging were not available for all
patient visits. For female patients age 15 years or greater, or male patients age 17 years or
greater, the height velocity PCDAI component was assigned as score of “0” because even a
height velocity of 0 cm/year was greater than 1 SD below the mean. For the weight
component, we used a historic weight recorded 4–6 months prior to the visit in order to
assign the PCDAI weight score. We did not take into account weight loss which may have
occurred due to corticosteroid withdrawal.
Data analysis
We used standard descriptive statistics to summarize the demographic characteristics of
included patients. We then assessed the feasibility of measuring the PCDAI, the APCDAI,
and the individual components of the PCDAI in the context of routine clinical care by
determining the proportion of visits for which each index (or individual component) could
be assigned a score. Next, we evaluated the relationship between the PCDAI and Physician
Global Assessment (PGA) in our study population. For visits in which each of the
components of the PCDAI and the PGA were completed, we used box and whisker plots and
descriptive statistics to analyze the distribution of PCDAI scores across the following
categories of PGA: inactive, mild, moderate, and severe.
In order to create a short index with improved feasibility, we examined the distribution of
responses for each component of the PCDAI and retained only those components that were
completed in ≥80% of visits. This led to removal of the items that were more often
incomplete including perirectal exam, height velocity, and laboratory values. Thus, our final
short index, included the following 6 components of the original PCDAI: abdominal pain,
patient functioning/general well-being, stools, weight, abdominal exam, and extra-intestinal
manifestations.
Next, to determine whether re- weighting of any of the individual components would
improve the overall accuracy of the short index, we randomly split the visits into a training
set and a validation set. In the training set, we created linear regression models using each of
the component scores as independent variables and the log-transformed full PCDAI score as
the dependent variable. Log transformation of the full PCDAI score was necessary as these
scores were not normally distributed. A value of 0.5 was added to the full PCDAI score
values prior to log transformation to account for values of 0. The components of the short
index that were most strongly associated with the log-transformed total PCDAI score were
identified from the size of the standardized regression parameters in the fitted multivariable
model. Standardized regression parameters, rather than unstandardized β coefficients, were
utilized to account for differences in standard errors between each of the components. These
components were then weighted according to the magnitude of the standardized regression
coefficients.
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We then validated this component weighting strategy in the validation set using a two step
process. First, we confirmed that the three items identified for weighting in the training set
had similar standardized regression parameters in the validation set. Next, we compared the
weighting schema selected in the training set with alternative weighting schema using
Pearson’s correlation to measure the association between each schema and the log-
transformed PCDAI in the validation set. We decided, a. priori, that if the correlation of the
weighting schema identified in the training set was equal to or greater than that of the
alternative weighting schema in the validation set, we would retained the original weighting
strategy assigned during the training phase. To confirm that the selected weighting schema
was not overly influenced by repeated measures within individual subjects, we repeated the
training and validation procedures using only the first visit for each eligible subject and
obtained similar results.
Finally, we evaluated the feasibility and performance of the Short PCDAI in the full set of
visits. We assessed the overall feasibility of the Short PCDAI by determining the proportion
of total visits for which the Short PCDAI could be assigned a score. We then measured the
correlation between the Short PCDAI and a number of other indicators of disease severity
including PCDAI, abbreviated PCDAI, PGA, hemoglobin, ESR, and albumin. Pearson’s
correlation was used to assess correlation with log transformed continuous measures
(PCDAI and abbreviated PCDAI), and Spearman correlation was used for ordinal variables
(PGA, lab parameters) We further characterized the distribution of Short PCDAI scores
across different PGA categories using means (s.d.), medians (IQ range), and box and
whisker plots. In addition, we used receiver operating characteristic (ROC) curves to test the
discriminant ability of the Short PCDAI and other indices to distinguish between inactive
and mild disease and between mild and moderate-severe disease. Finally, we calculated the
sensitivity and specificity of the Short PCDAI for discriminating between inactive and mild
disease and between mild and moderate-severe disease at different cut-points.
All statistical analyses were performed using SAS version 9.2 (SAS Institute: Cary, NC).
The study protocol was approved by all sites participating in the collaborative, and informed
consent was obtained if required by institutional IRB.
Results
Patient Demographics
This study included a total of 1355 subjects with Crohn’s disease, comprising a total of 6373
visits. The mean age was 14.2 years (SD. 3.3). Fifty-six percent were male, and the racial/
ethnic distribution was as follows: 74% white, 10% black, 2 % Hispanic, and 14% not
identified or other. The mean number of visits per patient was 4.5 (s.d. 3.6).
Feasibility of PCDAI and APCDAI
The PCDAI scores for each component of the index, as well as the proportion of visits for
which each component could be assigned a score, is displayed in Table 1. All 11
components of the PCDAI were complete in only 1067 of the 6373 visits (16.7%). The
abbreviated PCDAI was completed in 2811 out of 6373 visits (44.1%). PCDAI components
completed in less than 80% of visits included albumin, hemoglobin, sedimentation rate,
height velocity, and perirectal examination.
Relationship of PCDAI Score and Physician Global Assessment
The distribution of PCDAI scores across the following categories of PGA: inactive, mild,
moderate, and severe are displayed as box and whisker plots in Figure 1a. The mean (s.d.)
PCDAI scores (0–100 scale) for patients with inactive, mild, moderate, and severe disease
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were 7.0 (7.1), 18.3 (10.8), 26.2 (11.4), and 40.5 (14.2), respectively. As shown in the figure
and consistent with prior literature, there is overlap of PCDAI scores across PGA categories,
but the PCDAI is a reasonable instrument to discriminate between PGA categories.
Development of a Short PCDAI
Retaining all elements of the abbreviated PCDAI with a feasibility ≥80% resulted in a short
index containing the following components: abdominal pain, patient functioning/general
well-being, stools, weight, abdominal exam, and extra-intestinal manifestations. In the
training set, three items (patient functioning/general well-being, abdominal pain, and
weight) were most strongly associated with the log-transformed total PCDAI score
(standardized regression parameters approximately twice that of the other components), and
considered as candidate items to receive a higher weighting. Based on this, a value of 20
points was selected for these three items (twice the weight of the other components) (Table
2). To validate this weighting strategy, we confirmed that 1) these components had the
highest standardized regression parameters in the validation set, and 2) that the Pearson
correlation between the re-weighted Short index and the log-transformed full PCDAI was
equal to or greater than several alternative weighting strategies (data not shown). After
repeating the training and validation procedures using only the first visit for each subject, we
confirmed that the optimal component weighting did not change, suggesting that the
weighting schema selected was not overly influenced by repeated measures within
individual subjects.
Evaluation of the Short PCDAI
Overall, the Short PCDAI could be completed in 4241 out of 6373 visits, resulting in
feasibility 66.5% (compared with 16.7% for the full index and 44.1% in the abbreviated
index). The correlation between the Short PCDAI and disease severity assessed by PGA was
similar to that of the full PCDAI (r= 0.60, p<0.001 vs 0.61, p < 0.001). The correlation
between the Short PCDAI and the log transformed PCDAI and Abbreviated PCDAI were
0.66 and 0.84 respectively. Correlations with laboratory indicators of disease activity are
shown in Table 3. Box and whisker plots demonstrating the relationship between the Short
PCDAI and PGA are shown in figure 1b. The mean (s.d.) Short PCDAI scores for patients
with inactive, mild, and moderate to severe disease are 6.1 (8.7), 19.5 (13.3), 31.6 (17.1),
and 47.3 (16.0), respectively. Additionally, the area under the curve values generated from
receiver operating characteristic (ROC) curves demonstrating the discriminant ability of the
Short PCDAI , PCDAI, and ABPCDAI in distinguishing between inactive and mild disease
and between mild and moderate-severe disease are displayed in Table 4. Discriminatory
capacity for the Short PCDAI is approximately the same as for the two expanded indices.
Finally, Table 5 shows the sensitivity and specificity of the Short PCDAI in discriminating
between inactive and mild disease and between mild and moderate-severe disease at
different cut-points. For discrimination between inactive and mild, we recommend a cut-
point of less than 15. For discrimination between moderate-severe and mild, we recommend
a cut-point of ≥ 30.
Discussion
In this large, multi-center study, we found that the completion of the Pediatric Crohn’s
Disease Activity Index and the Abbreviated PCDAI in the context of routine clinical care
was quite limited. The components of height velocity, laboratory data, and perirectal
examination were the major barriers to completion of these indices. We therefore created a
Short PCDAI by eliminating these components, and re-weighting the remaining components
to maximize the correlation of the Short PCDAI and the PCDAI. As compared to the full
index, this short index is more feasible to complete in the context of routine clinical care and
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has similar correlation to physician global assessment. The ability to discriminate between
inactive and mild disease and between mild and moderate-severe disease is also similar to
the full index.
Based on these properties, we believe the Short PCDAI is a promising tool for quality
improvement and observational research. It should allow providers to track their patient
outcomes over time in a more objective fashion, study how changes in their practices impact
patient outcomes, and even allow comparisons to be made to national performance standards
(i.e. benchmarking). In addition, this instrument should facilitate retrospective chart reviews
and prospective registry studies. Given the myriad of financial and ethical issues, along with
the practical issue of difficult recruitment, registries and other observational studies have
been a mainstay of clinical research in pediatric IBD for decades. Until now, a significant
limitation of such observational studies is the large amount of missing data resulting in
possible informational bias when PCDAI was used as an outcome measure, or the inherent
subjectivity incurred when Physician Global Assessment was the primary outcome. Hence,
the Short PCDAI may optimize the balance between feasibly and objectivity that is
necessary for observational research.
Our results regarding the limited ability to complete the PCDAI in the context of routine
clinical care are consistent with prior published studies. Turner et al recently published a
study indicating that the PCDAI could be completed in less than 50% of visits[12]. The
feasibility of the PCDAI reported in that study was higher than we report, perhaps owing to
differences in study design and setting. Turner’s study included patients in the Pediatric IBD
Collaborative Research Group, a select group of closely followed newly diagnosed children
with IBD. In contrast, rather than a “research study” where careful procedures were used to
optimize the completeness of data collected on a limited number of selected patients at
selected center, this was a study of actual clinical practice. Participating centers sought to
enroll 100% of their patients with Crohn’s disease, and the data in the ImproveCareNow
database reflect that captured during routine clinic visits. Therefore, it is not surprising that
the completeness of the different clinical indices reported in this study are lower than that
reported in other studies. In fact, this underscores the difference between the feasibility of
completing an index for a specific research study and the feasibility of completing an index
in actual clinical practice.
In our study, we also observed variation in the completeness of PCDAI components across
centers. This study included 15 centers, with the largest center contributing approximately
25% of included patients. Therefore, it is possible that this and other large centers might
have heavily influenced our results. However, the diversity of sites in the ImproveCareNow
collaborative reflect the settings in which pediatric IBD care is delivered in the real world
(large and small centers, private and academic practices, etc.)
Our short index differs from the APCDAI in that it does not require the perirectal
examination. Prior work has suggested that this component helps discriminate between
remission and recurrence with a sensitivity of 32% and a specificity of 98%[15]. We chose
to eliminate this item from our short index because this component of the physical
examination is neither indicated nor routinely completed at all outpatient visits.
Furthermore, inclusion of this element did not substantially improve the correlation with the
full index. Thus, we believe the overall benefit of increased feasibility achieved by
eliminating the perirectal exam component is worth this minor trade-off.
It was not possible to select an a. priori threshold for which items to retain in the Short
PCDAI. Rather, this threshold was decided after examining the distributions of responses for
each component item. If we included completed at less than 80% of visits, the ability to
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complete the Short PCDAI during routine clinical care would fall to less than two-thirds,
greatly limiting the utility of the index. Had we required higher completion rates, this would
have eliminated items which are clinically very important and components of most other
indices for pediatric and adult IBD (stools, general well-being). Hence, this threshold was
selected in order to balance completeness and clinical relevance.
As with the parent PCDAI, the ability of the Short PCDAI to discriminate between inactive
and mild disease and between mild and moderate-severe disease is somewhat limited
(Figure 1A and B). This is in part due to the fact that Physician Global Assessment is not a
true “gold standard”. Although used as a gold standard in this and other studies evaluating
clinical indices in IBD, the subjectivity of this reference limits the ability to actually
measure sensitivity and specificity. In a recent evaluation of the PCDAI, the sensitivity and
specificity in distinguishing inactive from mild disease was 0.81 and 0.68 respectively, and
in distinguishing between mild and moderate-severe was 0.71 and 0.83 respectively[17]. In
the present study, the discriminatory capability of the Short PCDAI was similar, though
slightly decreased. This is perhaps due to the fact that PGA was obtained from a large
number of practicing clinicians across 15 centers. Although this is a major strength of this
study, to the extent that assignment of PGA varies across providers, the sensitivity and
specificity of both the full and short index will be diminished. Therefore, the values reported
here likely represent a worst-case scenario. In summary, existing pediatric Crohn’s disease
activity indices including the PCDAI and APCDAI are of limited value during routine
clinical care, as many of the required elements are not always collected and recorded during
patient encounters. By retaining and re-weighting the most frequently collected items, we
have developed a Short PCDAI that is easier to complete at the point of care, has excellent
correlation to the full index, and appears to have a similar ability as the PCDAI to
discriminate between different levels of disease activity as measured by Physician Global
Assessment. We expect this standardized classification tool will facilitate observational
research, quality improvement, and clinical care.
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“Distribution of Pediatric Crohn’s Disease Activity Index (PCDAI) and Short PCDAI
Scores According to Disease Severity as Measured by Physician Global Assessment” In
these box and whisker plots, the + symbol denotes the mean activity index score for each
category of disease severity, the vertical boxes depict the range of scores from the 25th to
75th percentile, and the horizontal hash mark in the middle of the vertical box represents
median score. Figure 1A represents the PCDAI and Figure 1B represents the Short PCDAI.
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Table 1
Feasibility of PCDAI Components in Routine Clinical Care (N = 3,643 visits)
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Table 2
Short PCDAI Components and Weights
Component Weight




Abdominal exam 10 points
Extraintestinal manifestations 10 points
Total 90 points
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Table 3
Correlation of Short PCDAI with other Indicators of Crohn’s Disease Activity
PCDAI Abbreviated PCDAI Short PCDAI
Log-transformed PCDAI 0.83 0.68 0.66
Log-transformed Abbreviated PCDAI 0.75 0.86 0.84
Log-transformed Short PCDAI 0.72 0.83 0.86
PGA* 0.61 0.64 0.60
Albumin* 0.35 0.17 0.15
ESR* 0.40 0.24 0.23
Hemoglobin* 0.28 0.11 0.11
*
Spearman correlation performed for ordinal variables
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Table 4
Area Under the Curve (AUC) for Short PCDAI versus other Clinical Indices
Comparison Short PCDAI AUC (95% CI) Abbreviated PCDAI AUC (95% CI) PCDAI AUC (95% CI)
Inactive vs Mild 0.80 (0.78, 0.81) 0.82 (0.81, 8.84) 0.82 (0.79, 0.85)
Mild vs Moderate-Severe 0.72 (0.69, 0.75) 0.72 (0.68, 0.84) 0.72 (0.66, 0.78)
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Table 5




< 5 0.86 0.57
< 10 0.83 0.62
< 15 0.64 0.84
< 20 0.57 0.88
Mod-Severe vs Mild
≥ 20 0.81 0.43
≥ 25 0.70 0.63
≥ 30 0.64 0.73
≥ 35 0.52 0.84
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